A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
In order to apply human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) to regenerative medicine, the cells should be produced under restricted conditions conforming to GMP guidelines. Since the conventional culture system has some issues that need to be addressed to achieve this goal, we developed a novel culture system. We found that recombinant laminin-511 E8 fragments are useful matrices for maintaining hESCs and hiPSCs when used in combination with a completely xeno-free (Xf) medium, StemFit™. Using this system, hESCs and hiPSCs can be easily and stably passaged by dissociating the cells into single cells for long periods, without any karyotype abnormalities. Human iPSCs could be generated under feeder-free (Ff) and Xf culture systems from human primary fibroblasts and blood cells, and they possessed differentiation abilities. These results indicate that hiPSCs can be generated and maintained under this novel Ff and Xf culture system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of defined culture media with recombinant proteins instead of whole animal serum greatly increases process comparability and supply chain assurance [67,68,69].”
From Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies (2023) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Gene-modified therapies, including iPSC-derived products and CAR-T cells, present distinct biosafety and technical challenges for POC implementation (Nakagawa et al., 2014; Moradi et al., 2023).”
From Isolator-based point-of-care manufacturing: a practical solution for GMP-compliant cell and extracellular vesicles therapy production (2025) · cites this paper as Nakagawa et al., 2014
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Self-citationInduction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Self-citationEmbryonic Stem Cell Lines Derived from Human Blastocysts
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., & Jones, J. M. (1998) · Science · doi:10.1126/science.282.5391.1145 · Cited by 15,926
Generation of germline-competent induced pluripotent stem cells
Okita, K., Ichisaka, T., & Yamanaka, S. (2007) · Nature · doi:10.1038/nature05934 · Cited by 4,299
Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts
Nakagawa, M., Koyanagi, M., Tanabe, K., Takahashi, K., Ichisaka, T., Aoi, T., Okita, K., Mochiduki, Y., Takizawa, N., & Yamanaka, S. (2008) · Nature Biotechnology · doi:10.1038/nbt1374 · Cited by 2,380
A more efficient method to generate integration-free human iPS cells
Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K.-I., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1591 · Cited by 2,061 · cited 3×
“Moreover, hiPSCs were successfully established from primary fibroblasts, peripheral blood and cord blood under these conditions using episomal vectors 16,17 .”
BackgroundMethodA ROCK inhibitor permits survival of dissociated human embryonic stem cells
Watanabe, K., Ueno, M., Kamiya, D., Nishiyama, A., Matsumura, M., Wataya, T., Takahashi, J. B., Nishikawa, S., Nishikawa, S.-I., Muguruma, K., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1310 · Cited by 2,055
Self-citationFeeder-free growth of undifferentiated human embryonic stem cells
Xu, C., Inokuma, M. S., Denham, J., Golds, K., Kundu, P., Gold, J. D., & Carpenter, M. K. (2001) · Nature Biotechnology · doi:10.1038/nbt1001-971 · Cited by 1,870
Chemically defined conditions for human iPSC derivation and culture
Chen, G., Gulbranson, D. R., Hou, Z., Bolin, J. M., Ruotti, V., Probasco, M. D., Smuga-Otto, K., Howden, S. E., Diol, N. R., Propson, N. E., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1593 · Cited by 1,447 · cited 2×
“In addition, it is necessary to use defined culture system for the source of iPS cells, such as fibroblasts or blood cells 13,23 .”
BackgroundMethodEmbryonic stem cell trials for macular degeneration: a preliminary report
Schwartz, S. D., Hubschman, J.-P., Heilwell, G., Franco-Cardenas, V., Pan, C. K., Ostrick, R. M., Mickunas, E., Gay, R., Klimanskaya, I., & Lanza, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60028-2 · Cited by 1,409
Research works printed but not linked: 1
- Grigoriadis, A. E. et al. Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. Blood 115, 2769–2776 (2010). · DOI · Paper page
Cited by
Items 101–200 of 675
Protein-driven RNA nanostructured devices that function in vitro and control mammalian cell fate
Shibata, T., Fujita, Y., Ohno, H., Suzuki, Y., Hayashi, K., Komatsu, K. R., Kawasaki, S., Hidaka, K., Yonehara, S., Sugiyama, H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00459-x · Cited by 50
Kagita, A., Lung, M. S. Y., Xu, H., Kita, Y., Sasakawa, N., Iguchi, T., Ono, M., Wang, X. H., Gee, P., & Hotta, A. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.02.013 · Cited by 50
“We would like to thank Dr. Hidetoshi Sakurai for providing CiRA00396 iPSCs, Dr. Masato Nakagawa for providing 1383D2 iPSCs, CiRA FiT for providing Ff-XT28s05 iPSCs, and Dr. Peter Karagiannis for proofreading the manuscript.”
InfluentialGeneration of cDC-like cells from human induced pluripotent stem cells via Notch signaling
Makino, K., Long, M. D., Kajihara, R., Matsueda, S., Oba, T., Kanehira, K., Liu, S., & Ito, F. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003827 · Cited by 55
Induction of functional xeno-free MSCs from human iPSCs via a neural crest cell lineage
Kamiya, D., Takenaka-Ninagawa, N., Motoike, S., Kajiya, M., Akaboshi, T., Zhao, C., Shibata, M., Senda, S., Toyooka, Y., Sakurai, H., et al. (2022) · npj Regenerative Medicine · doi:10.1038/s41536-022-00241-8 · Cited by 57
Trapping of CDC42 C-terminal variants in the Golgi drives pyrin inflammasome hyperactivation
Nishitani‐Isa, M., Mukai, K., Honda, Y., Nihira, H., Tanaka, T., Shibata, H., Kodama, K., Hiejima, E., Izawa, K., Kawasaki, Y., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20211889 · Cited by 48
“Generation of iPSCs, iPS-MLs, and iPS-MPs iPSCs from patients with the CDC42R186C variant were generated from peripheral blood mononuclear cells (PBMCs; Patient 1) and fibroblasts (Patient 2) as described previously (Nakagawa et al., 2014).”
MethodTransplantation of iPSC-derived corneal endothelial substitutes in a monkey corneal edema model
Hatou, S., Sayano, T., Higa, K., Inagaki, E., Okano, Y., Sato, Y., Okano, H., Tsubota, K., & Shimmura, S. (2021) · Stem Cell Research · doi:10.1016/j.scr.2021.102497 · Cited by 49
Regenerative strategies for kidney engineering
Montserrat, N., Garreta, E., & Belmonte, J. C. I. (2016) · FEBS Journal · doi:10.1111/febs.13704 · Cited by 47
TRPV-1-mediated elimination of residual iPS cells in bioengineered cardiac cell sheet tissues
Matsuura, K., Seta, H., Haraguchi, Y., Alsayegh, K. N., Sekine, H., Shimizu, T., Hagiwara, N., Yamazaki, K., & Okano, T. (2016) · Scientific Reports · doi:10.1038/srep21747 · Cited by 44
Antisense Oligonucleotides Reduce RNA Foci in Spinocerebellar Ataxia 36 Patient iPSCs
Matsuzono, K., Imamura, K., Murakami, N., Tsukita, K., Yamamoto, T., Izumi, Y., Kaji, R., Ohta, Y., Yamashita, T., Abe, K., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.06.017 · Cited by 49
“They were cultured by the feeder-free and xenofree culture systems with StemFit (Ajinomoto) with penicillin/ streptomycin.(40)”
MethodLi, X., Ma, R.-Y., Gu, Q., Liang, L., Wang, L., Zhang, Y., Wang, X., Liu, X., Li, Z., Fang, J., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0863-8 · Cited by 44
A non-invasive method to generate induced pluripotent stem cells from primate urine
Geuder, J., Wange, L. E., Janjic, A., Radmer, J., Janssen, P., Bagnoli, J., Müller, S., Kaul, A., Ohnuki, M., & Enard, W. (2021) · Scientific Reports · doi:10.1038/s41598-021-82883-0 · Cited by 51
Low Immunogenicity and Immunosuppressive Properties of Human ESC- and iPSC-Derived Retinas
Yamasaki, S., Sugita, S., Horiuchi, M., Masuda, T., Fujii, S., Makabe, K., Kawasaki, A., Hayashi, T., Kuwahara, A., Kishino, A., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.02.021 · Cited by 43
Yano, H., Koga, K., Sato, T., Shinohara, T., Iriguchi, S., Matsuda, A., Nakazono, K., Shioiri, M., Miyake, Y., Kassai, Y., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.05.004 · Cited by 44
Song, L., Awari, D. W., Han, E. Y., Uche-Anya, E. N., Park, S.-H. E., Yabe, Y., Chung, W. K., & Yazawa, M. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0245 · Cited by 44
Chromatin remodeler CHD7 regulates the stem cell identity of human neural progenitors
MuhChyi, C., Sanosaka, T., Okuno, H., Zhou, Z., Koya, I., Banno, S., Andoh-Noda, T., Tabata, Y., Shimamura, R., Hayashi, T., et al. (2018) · Genes & Development · doi:10.1101/gad.301887.117 · Cited by 46
Human iPSC-derived renal collecting duct organoid model cystogenesis in ADPKD
Mae, S.-I., Hattanda, F., Morita, H., Nozaki, A., Katagiri, N., Ogawa, H., Teranaka, K., Nishimura, Y., Kudoh, A., Yamanaka, S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113431 · Cited by 44
Mu, A., Hira, A., Niwa, A., Osawa, M., Yoshida, K., Mori, M., Okamoto, Y., Inoue, K., Kondo, K., Kanemaki, M. T., et al. (2021) · Blood · doi:10.1182/blood.2020009111 · Cited by 41
Mitsuzawa, S., Zhao, C., Ikeguchi, R., Aoyama, T., Kamiya, D., Ando, M., Takeuchi, H., Akieda, S., Nakayama, K., Matsuda, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-68745-1 · Cited by 40
Evaluation of the immunogenicity of human iPS cell-derived neural stem/progenitor cells in vitro
Ozaki, M., Iwanami, A., Nagoshi, N., Kohyama, J., Itakura, G., Iwai, H., Nishimura, S., Nishiyama, Y., Kawabata, S., Sugai, K., et al. (2017) · Stem Cell Research · doi:10.1016/j.scr.2017.01.007 · Cited by 46
“Shinya Yamanaka and was maintained as described previously (Takahashi et al., 2007; Okita et al., 2013; Nakagawa et al., 2014).”
MethodClinical trials using dental stem cells: 2022 update
Song, W., Jin, L., Zhu, M., Wang, H., & Xia, D. (2023) · World Journal of Stem Cells · doi:10.4252/wjsc.v15.i3.31 · Cited by 53
Techniques of Human Embryonic Stem Cell and Induced Pluripotent Stem Cell Derivation
Lewandowski, J., & Kurpisz, M. K. (2016) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0385-y · Cited by 48
“This is also the reason for exchanging culture media with defined media; e.g., knockout serum replacement medium, mTeSR1 medium and xeno-free media such as NutriStem (Sugii et al. 2010), TeSR2 (Meng et al. 2012), Essential 8 (Chen et al. 2011) and StemFit (Nakagawa et al. 2014).”
BackgroundNakashima, Y., & Ōmasa, T. (2016) · BioResearch open access · doi:10.1089/biores.2016.0001 · Cited by 43
“) to enable the efficient formation of colonies by hiPSCs on recombinant laminin-511.(45) However, albumin in the culture medium promotes the secretion of ECM molecules such as collagen I, collagen IV, and HSPG.”
BackgroundSuzuki, K., Koyanagi‐Aoi, M., Uehara, K., Hinata, N., Fujisawa, M., & Aoi, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-46848-8 · Cited by 42
Iriyama, S., Yasuda, M., Nishikawa, S., Takai, E., Hosoi, J., & Amano, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-69558-y · Cited by 40
Nalbandian, M., Zhao, M., Sasaki‐Honda, M., Jonouchi, T., Lucena-Cacace, A., Mizusawa, T., Yasuda, M., Yoshida, Y., Hotta, A., & Sakurai, H. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.03.004 · Cited by 39
Combining Induced Pluripotent Stem Cells and Genome Editing Technologies for Clinical Applications
Chang, C.-Y., Ting, H.-C., Su, H., & Jeng, J. (2018) · Cell Transplantation · doi:10.1177/0963689718754560 · Cited by 41
Patient-derived induced pluripotent stem cells for modelling genetic retinal dystrophies
Foltz, L. P., & Clegg, D. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.09.002 · Cited by 39
Kikuchi, T., Kino-oka, M., Wada, M., Kobayashi, T., Kato, M., Takeda, S., Kubo, H., Ogawa, T., Sunayama, H., Tanimoto, K., et al. (2018) · Regenerative Therapy · doi:10.1016/j.reth.2018.08.004 · Cited by 37
“Human induced-pluripotent stem cells prepared from human fibroblasts (clone 201B7) [13] were provided by RIKEN (Tsukuba, Japan), and expanded by hand through several passages by a feeder-free method derived from the method previously described [14].”
MethodOkumura, T., Horie, Y., Lai, C.-Y., Lin, H.-T., Shoda, H., Natsumoto, B., Fujio, K., Kumaki, E., Okano, T., Ono, S., et al. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1273-2 · Cited by 37
Ishikawa, M., Aoyama, T., Shibata, S., Sone, T., Miyoshi, H., Watanabe, H., Nakamura, M., Morota, S., Uchino, H., Yoo, A. S., et al. (2020) · Cells · doi:10.3390/cells9030532 · Cited by 36
“Among various PSC culture methods, we decided to use StemFit/AK02N (Ajinomoto) as the culture medium, since PSCs rapidly grow in this medium from a single cell level, and Laminin511 E8 fragment (iMatrix-511, Nippi) as the adhesion substrate [26,28].”
MethodInfluentialEfficient production of trophoblast lineage cells from human induced pluripotent stem cells
Kojima, J., Fukuda, A., Taira, H., Kawasaki, T., Ito, H., Kuji, N., Isaka, K., Umezawa, A., & Akutsu, H. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2016.159 · Cited by 31
Hayashi, R., Ishikawa, Y., Katayama, T., Quantock, A. J., & Nishida, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-34845-2 · Cited by 38
CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs
Morishige, S., Mizuno, S., Ozawa, H., Nakamura, T., Mazahery, A. R., Nomura, K., Seki, R., Mouri, F., Osaki, K., Yamamura, K., et al. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02765-0 · Cited by 38
Nakatake, Y., Ko, S. B. H., Sharov, A. A., Wakabayashi, S., Murakami, M., Sakota, M., Chikazawa-Nohtomi, N., Ookura, C., Sato, S., Ito, N., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107655 · Cited by 44
Ye, K., Takemoto, Y., Ito, A., Onda, M., Morimoto, N., Mandai, M., Takahashi, M., Kato, R., & Osakada, F. (2020) · Scientific Reports · doi:10.1038/s41598-020-70979-y · Cited by 39
Sekine, K., Ogawa, S., Tsuzuki, S., Kobayashi, T., Ikeda, K., Nakanishi, N., Takeuchi, K., Kanai, E., Otake, Y., Okamoto, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73908-1 · Cited by 36
Irie, N., & Surani, M. A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-4017-2_16 · Cited by 33
Chen, Z., Xu, R.-G., Chen, P., & Wang, Q. (2020) · IEEE Transactions on Plasma Science · doi:10.1109/tps.2020.3019995 · Cited by 44
“PAM has some following advantages [148], [149]:”
Generation of functional conjunctival epithelium, including goblet cells, from human iPSCs
Nomi, K., Hayashi, R., Ishikawa, Y., Kobayashi, Y., Katayama, T., Quantock, A. J., & Nishida, K. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108715 · Cited by 35
Koide, T., Koyanagi‐Aoi, M., Uehara, K., Kakeji, Y., & Aoi, T. (2022) · iScience · doi:10.1016/j.isci.2022.104314 · Cited by 43
“We cultured the iPSC lines according to a previously described method (Nakagawa et al., 2014).”
MethodPhenotypic Drug Screening for Dysferlinopathy Using Patient-Derived Induced Pluripotent Stem Cells
Kokubu, Y., Nagino, T., Sasa, K., Oikawa, T., Miyake, K., Kume, A., Fukuda, M., Fuse, H., Tozawa, R., & Sakurai, H. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0280 · Cited by 36
Kamata, Y., Isoda, M., Sanosaka, T., Shibata, R., Ito, S., Okubo, T., Shinozaki, M., Inoue, M., Koya, I., Shibata, S., et al. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0269 · Cited by 39
“hiPSCs were maintained by the feeder-free iPSC culture method.(27) For gNS/PCs induction, hiPSCs were dissociated into single cells using TrypLE Select (Thermo Fisher Scientific) and reaggregated to form embryoid”
MethodRecellularization of organs: what is the future for solid organ transplantation?
Moser, P. T., & Ott, H. C. (2014) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000131 · Cited by 40
“Furthermore, incalculable risks of contamination from fibroblast and pathogens common to materials of animal origin have led to the development of feeder-free and xeno-free culture conditions [30].”
BackgroundComplement factor D targeting protects endotheliopathy in organoid and monkey models of COVID-19
Kawakami, E., Saiki, N., Yoneyama, Y., Moriya, C., Maezawa, M., Kawamura, S., Kinebuchi, A., Kono, T., Funata, M., Sakoda, A., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.09.001 · Cited by 36
Indana, D., Zakharov, A. P., Lim, Y., Dunn, A. R., Bhutani, N., Shenoy, V. B., & Chaudhuri, O. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.03.016 · Cited by 33
Alidadi, M., Barzgar, H., Zaman, M., Paevskaya, O. A., Metanat, Y., Khodabandehloo, E., & Moradi, V. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1491282 · Cited by 41
Nakanishi, H., & Saito, H. (2020) · Nature Communications · doi:10.1038/s41467-020-15061-x · Cited by 33
Netsrithong, R., García-Pérez, L., & Themeli, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1325209 · Cited by 44
Ten years of iPSC: clinical potential and advances in vitro hematopoietic differentiation
Paes, B. C. M. F., Moço, P. D., Pereira, C. G., Porto, G. S., Russo, E. M. D. S., Reis, L. C. J., Covas, D. T., & Picanço‐Castro, V. (2016) · Cell Biology and Toxicology · doi:10.1007/s10565-016-9377-2 · Cited by 37
Kuwahara, A., Yamasaki, S., Mandai, M., Watari, K., Matsushita, K., Fujiwara, M., Hori, Y., Hiramine, Y., Nukaya, D., Iwata, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55130-w · Cited by 35
Yamashita, A., Yoshitomi, H., Kihara, S., Toguchida, J., & Tsumaki, N. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0058 · Cited by 31
CiRA iPSC seed stocks (CiRA's iPSC Stock Project)
Hanatani, T., & Takasu, N. (2020) · Stem Cell Research · doi:10.1016/j.scr.2020.102033 · Cited by 32
Bioactive functional scaffolds for stem cells delivery in wound healing and skin regeneration
Hazrati, R., Davaran, S., & Omidi, Y. (2022) · Reactive and Functional Polymers · doi:10.1016/j.reactfunctpolym.2022.105233 · Cited by 36
Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies
Nath, S. C., Menendez, L., & Friedrich Ben-Nun, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316929 · Cited by 35
PAM-flexible Cas9-mediated base editing of a hemophilia B mutation in induced pluripotent stem cells
Hiramoto, T., Kashiwakura, Y., Hayakawa, M., Baatartsogt, N., Kamoshita, N., Abe, T., Inaba, H., Nishimasu, H., Uosaki, H., Hanazono, Y., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00286-w · Cited by 31
Miyagawa, S., Kawamura, T., Ito, E., Takeda, M., Iseoka, H., Yokoyama, J., Harada, A., Mochizuki‐Oda, N., Imanishi-Ochi, Y., Li, J., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03690-8 · Cited by 46
“…plasmids (pCE-hSK, pCE-hUL, pCE-hOCT3/4, pCE-mp53DD, and pCXB-EBNA1; Additional file 1: Table S3) [12] and maintained using a feeder-free and xeno-free culture system [13] in the cell processing center of the Center for iPS Cell Research and Application (CiRA; Kyoto University, Kyoto, Japan).”
MethodHuman iPSC for Therapeutic Approaches to the Nervous System: Present and Future Applications
Cefalo, M. G., Carai, A., Miele, E., Pò, A., Ferretti, E., Mastronuzzi, A., & Germano, I. M. (2015) · Stem Cells International · doi:10.1155/2016/4869071 · Cited by 35
“[38] were able to obtain an adequate number of footprint-free, xeno-free hiPSC clones from both skin-derived fibroblasts and blood cells.”
First proposal of minimum information about a cellular assay for regenerative medicine
Sakurai, K., Kurtz, A., Stacey, G., Sheldon, M., & Fujibuchi, W. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0393 · Cited by 31
Ferreira, A. F., Călin, G. A., Picanço‐Castro, V., Kashima, S. H., Covas, D. T., & de Castro, F. A. (2018) · Journal of Cell Science · doi:10.1242/jcs.203018 · Cited by 32
“Feeder cells can be replaced by human extracellular matrix proteins, and culture media containing serum can be replaced with a serum-free medium with recombinant molecules (Nakagawa et al., 2014, Warren and Wang et al., 2013).”
BackgroundStem cells for spinal cord injuries bearing translational potential
Seifalian, A. M., Dalamagkas, K., & Tsintou, M. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.224360 · Cited by 34
“Several steps have been taken towards that direction in order to surpass these obstacles, like the fact that an adequate number of iPSCs was produced without co-cultures or lenti virus (Nakagawa et al., 2014).”
BackgroundShiba, M., Higo, S., Kondo, T., Li, J., Liu, L., Ikeda, Y., Kohama, Y., Kameda, S., Tabata, T., Inoue, H., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab127 · Cited by 39
“iPS cells were maintained on laminin-coated plate with medium (StemFit AK02, AJINOMOTO) (49).”
Yokobayashi, S., Yabuta, Y., Nakagawa, M., Okita, K., Hu, B., Murase, Y., Nakamura, T., Bourque, G., Majewski, J., Yamamoto, T., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109909 · Cited by 30
Kim, M., Takeuchi, K., & Kino‐oka, M. (2018) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2018.08.010 · Cited by 38
Induced pluripotent stem (iPS) cells from human fetal stem cells (hFSCs)
Spinelli, V., Guillot, P. V., & Coppi, P. D. (2013) · Organogenesis · doi:10.4161/org.25197 · Cited by 33
Matsushita, M., Nakatake, Y., Arai, I., Ibata, K., Kohda, K., Goparaju, S. K., Murakami, M., Sakota, M., Chikazawa-Nohtomi, N., Ko, S. B. H., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.039 · Cited by 32
Application of induced pluripotent stem cells in epilepsy
Hirose, S., Tanaka, Y., Shibata, M., Kimura, Y., Ishikawa, M., Higurashi, N., Yamamoto, T., Ichise, E., Chiyonobu, T., & Ishii, A. (2020) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2020.103535 · Cited by 31
Townshend, R. F., Shao, Y., Wang, S., Cortez, C. L., Esfahani, S. N., Spence, J. R., O'Shea, K. S., Fu, J., Gumucio, D. L., & Taniguchi, K. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.588941 · Cited by 33
Pretemer, Y., Kawai, S., Nagata, S., Nishio, M., Watanabe, M., Tamaki, S., Alev, C., Yamanaka, Y., Xue, J., Wang, Z., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.01.014 · Cited by 31
“The expression of chondrocyte markers and the change in chondrocyte morphology during HI were similar in the 1231A3 iPSC line (Nakagawa et al., 2014) (Figures S1A–S1E).”
BackgroundZujur, D., Al-Akashi, Z., Nakamura, A., Zhao, C., Takahashi, K., Aritomi, S., Theoputra, W., Kamiya, D., Nakayama, K., & Ikeya, M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1140717 · Cited by 34
“Human iPSCs 1231A3 reprogrammed with episomal vectors (kindly provided by Yamanaka Laboratory) were maintained as described previously (Nakagawa et al., 2014).”
MethodChang, C.-Y., Ting, H.-C., Liu, C.-A., Su, H.-L., Chiou, T., Harn, H., & Lin, S. (2018) · Cell Transplantation · doi:10.1177/0963689718775406 · Cited by 33
Activin Is Superior to BMP7 for Efficient Maintenance of Human iPSC-Derived Nephron Progenitors
Tanigawa, S., Naganuma, H., Kaku, Y., Era, T., Sakuma, T., Yamamoto, T., Taguchi, A., & Nishinakamura, R. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.07.003 · Cited by 30
“coated with iMatrix-511 silk, as described previously (Nakagawa et al., 2014; Yoshimura et al., 2017).”
MethodWatanabe, D., Koyanagi‐Aoi, M., Taniguchi‐Ikeda, M., Yoshida, Y., Azuma, T., & Aoi, T. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0021 · Cited by 33
Motor neuron differentiation of iPSCs obtained from peripheral blood of a mutant TARDBP ALS patient
Bossolasco, P., Sassone, F., Gumina, V., Peverelli, S., Garzo, M., & Silani, V. (2018) · Stem Cell Research · doi:10.1016/j.scr.2018.05.009 · Cited by 31
Ocular surface ectoderm instigated by WNT inhibition and BMP4
Kobayashi, Y., Hayashi, R., Shibata, S., Quantock, A. J., & Nishida, K. (2020) · Stem Cell Research · doi:10.1016/j.scr.2020.101868 · Cited by 31
“Cells were passaged every seven days, changing the medium every two days (Nakagawa et al., 2014).”
BackgroundImpaired NEPHRIN localization in kidney organoids derived from nephrotic patient iPS cells
Ohmori, T., De, S., Tanigawa, S., Miike, K., Islam, M., Soga, M., Era, T., Shiona, S., Nakanishi, K., Nakazato, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83501-9 · Cited by 33
Cell-Derived Extracellular Matrix Materials for Tissue Engineering
Guan, Y., Yang, B., Xu, W., Li, D., Wang, S., Ren, Z., Zhang, J., Zhang, T., Liu, X., Li, J., et al. (2022) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2021.0147 · Cited by 33
Neuroprotection of Stem Cells Against Ischemic Brain Injury: From Bench to Clinic
Liu, X., & Jia, X. (2023) · Translational Stroke Research · doi:10.1007/s12975-023-01163-3 · Cited by 32
“Therefore, iPSCs have fewer ethical challenges regarding their transplantation [70].”
iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome
Hirayama, R., Toyohara, K., Watanabe, K., Otsuki, T., Araoka, T., Mae, S.-I., Horinouchi, T., Yamamura, T., Okita, K., Hotta, A., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05203-4 · Cited by 28
García-Robledo, J. E., Cabrera-Salcedo, S. C., Brandauer, A. M., Romano, F., Rengifo-Martinez, J., Toro-Pedroza, A., Hincapie, J. S. V., Ríos-Serna, L. J., Loukanov, A. R., Cardona, A. F., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1698442 · Cited by 45
Isoda, M., Kohyama, J., Iwanami, A., Sanosaka, T., Sugai, K., Yamaguchi, R., Matsumoto, T., Nakamura, M., & Okano, H. (2016) · Neuroscience Research · doi:10.1016/j.neures.2016.04.003 · Cited by 31
Hosaka, C., Kunisada, M., Koyanagi‐Aoi, M., Masaki, T., Takemori, C., Taniguchi‐Ikeda, M., Aoi, T., & Nishigori, C. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12779 · Cited by 32
Current Developments in the Stable Production of Human Induced Pluripotent Stem Cells
Horiguchi, I., & Kino‐oka, M. (2021) · Engineering · doi:10.1016/j.eng.2021.01.001 · Cited by 30
“molecules, such as the laminin-511 fragment [48,49] and vitronectin fragment [50], have been developed recently.”
BackgroundYoshimatsu, M., Ohnishi, H., Zhao, C., Hayashi, Y., Kuwata, F., Kaba, S., Okuyama, H., Kawai, Y., Hiwatashi, N., Kishimoto, Y., et al. (2020) · Stem Cell Research · doi:10.1016/j.scr.2021.102233 · Cited by 29
The pluripotent stem cell-specific transcript ESRG is dispensable for human pluripotency
Takahashi, K., Nakamura, M., Okubo, C., Kliesmete, Z., Ohnuki, M., Narita, M., Watanabe, A., Ueda, M., Takashima, Y., Hellmann, I., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009587 · Cited by 28
“H9 ESC (RID:CVCL_9773) [52] and 585A1 iPSC (RRID:CVCL_DQ06) [53] lines were maintained in StemFiT AK02 media (Ajinomoto) supplemented with 100 ng/ml recombinant human basic fibroblast growth factor (bFGF, Peprotech) (hereafter F/A media) on a tissue culture plate coated with Laminin 511 E8 fragment (LN511E8, NIPPI) [5…”
MethodHua, Y., Yoshimochi, K., Li, J., Takekita, K., Shimotsuma, M., Li, L., Qu, X., Zhang, J., Sawa, Y., Liu, L., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02879-z · Cited by 29
“StemFit® AK02N medium (AK02N, Ajinomoto, Japan) is an albumin-containing xeno-free medium that is made to be used with laminin-511 E8 fragment (LM511-E8) substrate [28].”
BackgroundMethodInfluentialPlasma-activated medium selectively eliminates undifferentiated human induced pluripotent stem cells
Matsumoto, R., Shimizu, K., Nagashima, T., Tanaka, H., Mizuno, M., Kikkawa, F., Hori, M., & Honda, H. (2016) · Regenerative Therapy · doi:10.1016/j.reth.2016.07.001 · Cited by 28
“These cells were passaged after dissociation into single cells with TrypLE Select CTS (A12859-01; Life Technologies, California, USA) [30].”
MethodIshida, K., Xu, H., Sasakawa, N., Lung, M. S. Y., Kudryashev, J. A., Gee, P., & Hotta, A. (2018) · Scientific Reports · doi:10.1038/s41598-017-18568-4 · Cited by 30
Establishment of a Robust Platform for Induced Pluripotent Stem Cell Research Using Maholo LabDroid
Sasamata, M., Shimojo, D., Fuse, H., Nishi, Y., Sakurai, H., Nakahata, T., Yamagishi, Y., & Sasaki-Iwaoka, H. (2021) · SLAS TECHNOLOGY · doi:10.1177/24726303211000690 · Cited by 28
Sharma, A., Mücke, M. B., & Seidman, C. E. (2018) · Current Protocols in Molecular Biology · doi:10.1002/cpmb.58 · Cited by 28
Panula, S., Kurek, M., Kumar, P., Albalushi, H. M. A., Sánchez, S. P., Damdimopoulou, P., Olofsson, J. I., Hovatta, O., Lanner, F., & Stukenborg, J. (2019) · Human Reproduction · doi:10.1093/humrep/dez134 · Cited by 27
Oh, S., Jeong, Y.-W., Choi, W., Noh, J., Lee, S., Kim, H. S., & Song, J. (2020) · Stem Cells International · doi:10.1155/2020/4061516 · Cited by 30
“iPSCs can be generated from different types of somatic cells, including skin fibroblasts, keratinocytes, or peripheral blood [8].”
BackgroundMethodTakahashi, K., Jeong, D., Wang, S., Narita, M., Jin, X., Iwasaki, M., Perli, S. D., Conklin, B. R., & Yamanaka, S. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107715 · Cited by 25
“Human iPSCs were routinely maintained on recombinant laminin 511 E8 fragment (LN511, Nippi)-coated plate in StemFiT media (Ajinomoto) supplemented with 100 ng/ml recombinant basic fibroblast growth factor (bFGF, Peprotech) (hereafter F/A media) (Miyazaki et al., 2012; Nakagawa et al., 2014).”
MethodStem cell therapies for spinal cord injury in humans: A review of recent clinical research
Sugai, K., Nakamura, M., Okano, H., & Nagoshi, N. (2025) · Brain and Spine · doi:10.1016/j.bas.2025.104207 · Cited by 26
“Cord blood cells or adult peripheral blood cells are considered ideal cell sources for these cells (Nakagawa et al., 2014).”
Dzhoyashvili, N. A., Shen, S., & Rochev, Y. A. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201400798 · Cited by 28
Nishimura, K., Doi, D., Samata, B., Murayama, S., Tahara, T., Onoe, H., & Takahashi, J. B. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.02.008 · Cited by 34
Yamashita, T., Miyamoto, Y., Bandô, Y., Ono, T., Kobayashi, S., Ayano, D., Araki, T., Kato, Y., Shirakawa, T., Suzuki, Y., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171947 · Cited by 30
Nakanishi, H., Miki, K., Komatsu, K. R., Umeda, M., Mochizuki, M., Inagaki, A., Yoshida, Y., & Saito, H. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.02.033 · Cited by 25
Iwasawa, C., Tamura, R., Sugiura, Y., Suzuki, S., Kuzumaki, N., Narita, M., Suematsu, M., Nakamura, M., Yoshida, K., Toda, M., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040810 · Cited by 27
“, Kyoto, Japan) were cultured with a feeder-free protocol [53].”
MethodDarabi, R., & Perlingeiro, R. C. R. (2014) · Methods in molecular biology · doi:10.1007/7651_2014_134 · Cited by 29
Current status and future directions of clinical applications using iPS cells—focus on Japan
Tsujimoto, H., & Osafune, K. (2021) · FEBS Journal · doi:10.1111/febs.16162 · Cited by 30
Metadata
- Authors
- Nakagawa, M., Taniguchi, Y., Senda, S., Takizawa, N., Ichisaka, T., Asano, K., Morizane, A., Doi, D., Takahashi, J., Nishizawa, M., Yoshida, Y., Toyoda, T., Osafune, K., Sekiguchi, K., & Yamanaka, S.
- Affiliations
- Kyoto University (JP)
- Institute for Protein Research, The University of Osaka (JP)
- Ajinomoto (Japan) (JP)
- Gladstone Institutes (US)
- Corresponding author
- Nakagawa, Masato
- ORCID
- Venue
- Scientific Reports
- Published
- 2014-01-08
- Volume
- 4
- Issue
- 1
- Pages
- 3594-3594
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC3884228
- OpenAlex
- W1972564906
- Cited by
- 673
- References
- 30
- Citations by year
- 2026: 35 · 2025: 46 · 2024: 74 · 2023: 66 · 2022: 65 · 2021: 76 · 2020: 66 · 2019: 49 · 2018: 37 · 2017: 58 · 2016: 47 · 2015: 39 · 2014: 14
- FWCI
- 21.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/3.0/ (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- OUKA (Osaka University Knowledge Archive) (Osaka University) (submittedVersion)
- Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by-nc-nd)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science (25860747, 24790277, 24590353, 24592124, 25291026)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Keywords
- induced pluripotent stem cells, feeder-free culture, xeno-free culture, human embryonic stem cells, primary fibroblasts, blood cells, karyotype stability, cell dissociation, differentiation potential
- MeSH terms
- Cell Differentiation, Culture Media, Humans, Serial Passage, Cell Culture Techniques, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.